Loading
This European trial, like its American counterpart, found that replacing cisplatin with cetuximab in low-risk HPV-positive oropharyngeal cancer caused more recurrences and deaths without reducing severe toxicity.
Phase 3 trial of 334 patients with low-risk HPV-positive oropharyngeal cancer (non-smokers or light smokers) randomised to radiotherapy 70 Gy with cisplatin or with cetuximab, with severe toxicity as the primary endpoint.
Severe toxicity did not differ, while two-year overall survival was 97.5 percent with cisplatin against 89.4 percent with cetuximab (hazard ratio 5.0) and recurrence was 6.0 versus 16.1 percent.
Cetuximab is not an acceptable substitute for cisplatin in HPV-positive disease; de-escalation must be tested through other routes such as dose reduction after response or surgery-based pathways.
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue), Cetuximab, The Lancet.
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue), Cisplatin.
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue), Cetuximab, Cisplatin.
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue).
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue).
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue), Cisplatin.
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue), Cisplatin.
Shares The Lancet, Cisplatin.